Download PDF
Thromb Haemost 1993; 69(04): 375-380
DOI: 10.1055/s-0038-1651615
Original Article
Coagulation
Schattauer GmbH Stuttgart

Recombinant Pro-Urokinase Requires Heparin for Optimal Clot Lysis and Restoration of Blood Flow in a Canine Femoral Artery Thrombosis Model

Sandra E Burke
1   The Department of General Pharmacology, Abbott Park, IL, USA
,
Nathan L Lubbers
1   The Department of General Pharmacology, Abbott Park, IL, USA
,
Richard A Nelson
1   The Department of General Pharmacology, Abbott Park, IL, USA
,
Jack Henkin
2   Thrombolytic Venture, Abbott Laboratories, Abbott Park, IL, USA
› Author Affiliations
Further Information

Publication History

Received 11 September 1991

Accepted after revision 04 December 1992

Publication Date:
05 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Heparin is often used as an adjunct to thrombolytic therapy in order to prevent reocclusion of the patent vessels in patients with thrombotic disease. Controversy exists as to whether heparin is required for effective clot lysis with tissue-type plasminogen activator, while in vitro data and small scale clinical trials have suggested an enhancement of pro-urokinase efficacy by heparin. The present study was conducted to determine whether heparin pre-treatment is required to produce optimal clot lysis and blood flow restoration in response to recombinant pro-urokinase (r-proUK). In four groups of dogs, blood clots labelled with 125Iodine were formed in the femoral artery and were monitored continuously for loss of counts as an indicator of clot lysis. Femoral artery blood flow was measured simultaneously. Group 1 received vehicle (n = 5), while group 2 was given vehicle + heparin (n = 6; 500 U bolus + 350 U/h). This dose of heparin increased the activated partial thromboplastin time (APTT) by at least 1.5 times the control level for the 4 h observation period. Group 3 received r-proUK alone at a dose of 100,000 U/kg (50% given as a 1-min bolus injection, 50% as a 30 min infusion) (n = 8), while group 4 was treated with the same dose of r-proUK in the presence of heparin as described (n = 8). Clot lysis at 4 h in groups 1 and 2 was 26 ± 3% and 28 ± 5%, respectively; flow was not restored in either group. In group 3, clot lysis was 50 ± 4% while group 4 showed lysis of 85 ± 5% (p <0.05). However, flow was not restored in any dog in group 3, while five of eight dogs in group 4 showed complete restoration of blood flow. In the remaining three dogs, flow was restored to 70–91% of control levels. The data suggest that a regimen of heparin pretreatment with continued infusion markedly increases the efficacy of r-proUK in this model and results in significant restoration of blood flow.

 

  • References

  • 1 Pannell R, Gurewich V. Pro-urokinase: A study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood 1986; 67: 1215-1223
    PubMedGoogle Scholar
  • 2 Loscalzo J, Wharton TP, Kirshenbaum JM, Levine HJ, Flaherty JT, Topol EJ, Ramaswamy K, Kosowsky BD, Salem DN, Ganz P, Brinker JA, Gurewich V, Muller JE. Clot-selective coronary thrombolysis with pro-urokinase. Circulation 1989; 79: 776-782
    CrossrefPubMedGoogle Scholar
  • 3 Gurewich V, Pannell R, Louie S, Kelley P, Suddith RL, Greenlee R. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species. J Clin Invest 1984; 73: 1731-1739
    CrossrefPubMedGoogle Scholar
  • 4 Van de Werf F, Jang IK, Collen D. Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-reponse in dogs with coronary artery thrombolysis. J Cardiovasc Pharmacol 1987; 9: 91-93
    PubMedGoogle Scholar
  • 5 Van de Werf F, Nobuhara M, Collen D. Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (prourokinase) in patients with acute myocardial infarction. Ann Intern Med 1986; 104: 345-348
    CrossrefPubMedGoogle Scholar
  • 6 Trübestein G, Popov S, Wolf H, Welzel D. Effects of pro-urokinase and urokinase on the fibrinolytic system in man. Haemostasis 1987; 17: 238-244
    PubMedGoogle Scholar
  • 7 Prins MH, Hirsh J. Heparin as an adjunctive treatment after thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1991; 67: 3A-11A
    CrossrefPubMedGoogle Scholar
  • 8 Cercek B, Lew AS, Hod H, Yano J, Reddy NKN, Ganz W. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. Circulation 1986; 74: 583-587
    CrossrefPubMedGoogle Scholar
  • 9 Tomaru T, Uchida Y, Nakamura F, Sonoki H, Tsukamoto M, Sugimoto T. Enhancement of arterial thrombolysis with native tissue type plasminogen activator by pretreatment with heparin or batroxobin: An angioscopic study. Am Heart J 1989; 117: 275-281
    CrossrefPubMedGoogle Scholar
  • 10 Rapold HJ, Lu HR, Wu Z, Nijs H, Collen D. Requirement of heparin for arterial and venous thrombolysis with recombinant tissue-type plasminogen activator. Blood 1991; 77: 1020-1024
    PubMedGoogle Scholar
  • 11 Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990; 323: 1433-1437
    CrossrefPubMedGoogle Scholar
  • 12 Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990; 66: 1412-1417
    CrossrefPubMedGoogle Scholar
  • 13 Agnelli G, Pascucci C, Cosmi B, Nenci GG. Effects of therapeutic doses of heparin on thrombolysis with tissue-type plasminogen activator in rabbits. Blood 1990; 76: 2030-2036
    PubMedGoogle Scholar
  • 14 Görög P, Ridler CD, Kovacs IB. Heparin inhibits spontaneous thrombolysis and the thrombolytic effect of both streptokinase and tissue-type plasminogen activator.An in vitro study of the dislodge-ment of platelet-rich thrombi formed from native blood. J Intern Med 1990; 227: 125-132
    CrossrefPubMedGoogle Scholar
  • 15 Topol EJ, George BS, Kereiakes DJ, Stump DC, Candela RJ, Abbottsmith CW, Aronson L, Pickel A, Boswick JM, Lee KL, Ellis SG, Califf RM. The TAMI Study Group. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989; 79: 281-286
    CrossrefPubMedGoogle Scholar
  • 16 Stassen JM, Juhan-Vague I, Alessi MC, De Cock F, Collen D. Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single chain urokinase-type plasminogen activator. Thromb Haemostas 1987; 58: 947-950
    PubMedGoogle Scholar
  • 17 Gulba DC, Fischer K, Reil G-H, Daniel WG, Lichtlen PR. Potentiation of the thrombolytic efficacy of single-chain urokinase (prourokinase) by heparin. Thromb Haemostas 1988; 60: 350-351
    PubMedGoogle Scholar
  • 18 Gulba DC, Fischer K, Barthels M, Jost S, Möller W, Frombach R, Reil G-H, Daniel WG, Lichtlen PR. Potentiative effect of heparin in thrombolytic therapy of evolving myocardial infarction with natural pro-urokinase. Fibrinolysis 1989; 3: 165-173
    PubMedGoogle Scholar
  • 19 Badylak SF, Poehlman ET, Williams C, Klabunde RE, Turek J, Schoenlein W. A simple canine model of arterial thrombosis with endothelial injury suitable for investigation of thrombolytic agents. J Pharmacol Methods 1988; 19: 293-304
    CrossrefPubMedGoogle Scholar
  • 20 Lo K-M, Gillies SD. High level expression of human proteins in murine hybridoma cells: induction by methotrexate in the absence of gene amplification. Biochim Biophys Acta 1991; 1088: 217-224
    CrossrefPubMedGoogle Scholar
  • 21 Sutherland JW, Banick DW, Schmakel CO. Stabilized procedure for the determination of urokinase fibrinolytic potency. Anal Biochem 1991; 194: 121-129
    CrossrefPubMedGoogle Scholar
  • 22 Friberger P, Knös M. Plasminogen determination in human plasma. In: Chromogenic Peptide Substrates: Chemical and Clinical Usage. Scully MF, Kakkar VV. (eds) Churchill Livingstone, Edinburgh: 1979: 128-140
  • 23 Edy J, De Cock F, Collen D. Inhibition of plasmin by normal and antiplasmin-depleted human plasma. Thromb Res 1976; 8: 513-518
    CrossrefPubMedGoogle Scholar
  • 24 Rampling MW, Gaffney PJ. The sulfite precipitation method for fibrinogen measurement; its use on small samples in the presence of fibrinogen degradation products. Clin Chem Acta 1976; 67: 43-52
    CrossrefPubMedGoogle Scholar
  • 25 Tukey JW, Ciminera JL, Heyse JE. Testing the statistical certainty of a response to increasing doses of a drug. Biometrics 1985; 4l: 295-301
    PubMedGoogle Scholar
  • 26 Gurewich V, Pannell R, Greenlee R, Suddith R. The fibrin specificity of single chain urokinase (SC-UK) induced proteolysis is not dependent on fibrin binding. Thromb Haemostas 1983; 50: 386
    PubMedGoogle Scholar
  • 27 Flameng W, Vanhaecke J, Stump DC, Van de Werf F, Holmes W, Guenzler WA, Flohe L, Collen D. Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator of recombinant urokinase in baboons: Effect on regional blood flow, infarct size and hemostasis. J Am Coll Cardiol 1986; 8: 118-124
    CrossrefPubMedGoogle Scholar
  • 28 Collen D, Stassen JM, Blaber M, Winkler M, Verstraete M. Biological and thrombolytic properties of proenzyme and active forms of human urokinase – III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis. Thromb Haemostas 1984; 52: 27-30
    PubMedGoogle Scholar
  • 29 Voytik S, Badylak SF, Burke S, Klabunde RE, Henkin J, Simmons A. The protective effect of heparin in a dog model of rethrombosis following pharmacologic thrombolysis. Thromb Haemostas 1990; 64: 438-444
    PubMedGoogle Scholar
  • 30 Badylak SF, Voytik SL, Henkin J, Burke SE, Sasahara AA, Simmons A. Enhancement of the thrombolytic efficacy of prourokinase by lys-plasminogen in a dog model of arterial thrombosis. Thromb Res 1991; 62: 115-126
    CrossrefPubMedGoogle Scholar
  • 31 Gulba DC, Barthels M, Westhoff-Bleck M, Jost S, Rafflenbeul W, Daniel WG, Hecker H, Lichtlen PR. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Circulation 1991; 83: 937-944
    CrossrefPubMedGoogle Scholar
  • 32 Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER. Thrombolytic therapy with tissue plasminogen activator or streptokinase induced transient thrombin activity. Blood 1988; 72: 616-620
    PubMedGoogle Scholar
  • 33 Eisenberg PR, Sherman LA, Jaffe AS. Paradoxic elevation of fibrinopeptide A after streptokinase: Evidence for continued thrombosis despite intense fibrinolysis. J Am Coll Cardiol 1987; 10: 527-529
    CrossrefPubMedGoogle Scholar
  • 34 Gurewich V, Pannell R. Inactivation of single-chain urokinase (prourokinase) by thrombin and thrombin-like enzymes: relevance of the findings to the interpretation of fibrin-binding experiments. Blood 1987; 69: 769-772
    PubMedGoogle Scholar
  • 35 Ichinose A, Fujikawa K, Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 1986; 261: 3486-3489
    PubMedGoogle Scholar
  • 36 Broeze R, Abercrombie D, Buchinski B, Salvato K, Stumo D, Vovis G. Fibrinolysis by two-chain urokinase-type plasminogen activator cleaved at arginine-156 by thrombin. Fibrinolysis 1988; 2 (Suppl. 01) 153
    PubMedGoogle Scholar
  • 37 Collen D, Dewerchin D, Stassen JM, Kieckens L, Lijnen HR. Thrombolytic and pharmacokinetic properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for crosslinked fibrin. Fibrinolysis 1989; 3: 197-202
    PubMedGoogle Scholar
  • 38 Andrade-Gordon P, Strickland S. Interaction of heparin with plasminogen activators and plasminogen: Effects on the activation of plasminogen. Biochemistry 1986; 25: 4033-4040
    CrossrefPubMedGoogle Scholar
  • 39 Grailhe P, Anglés-Cano D. The activation of plasminogen by tissue plasminogen activator is not enhanced by different heparin species as assessed in vitro with a solid-phase fibrin method. Fibrinolysis 1991; 5: 61-69
    PubMedGoogle Scholar
  • 40 Fry ETA, Sobel BE. Lack of interference by heparin with thrombolysis or binding of tissue-type plasminogen activator to thrombi. Blood 1988; 71: 1347-1352
    PubMedGoogle Scholar
  • 41 Weitz JI, Kuint J, Leslie B, Hirsh J. Standard and low molecular weight heparin have no effect on tissue plasminogen activator induced plasma clot lysis or fibrinogenolysis. Thromb Haemostas 1991; 65: 541-544
    PubMedGoogle Scholar
  • 42 Dosne AM, Bendetowicz AV, Kher A, Samama M. Marked potentiation of the plasminogenolytic activity of pro-urokinase by unfractionated heparin and a low molecular-weight heparin. Thromb Res 1988; 51: 627-630
    CrossrefPubMedGoogle Scholar
  • 43 Marsh NA, Minter AJ, Chesterman CN. The effect of heparin and other glycosaminoglycans on levels of tissue plasminogen activator and plasminogen activator inhibitor in cultured human umbilical vein endothelial cells. Blood Coagul Fibrinol 1990; 1: 133-138
    PubMedGoogle Scholar
  • 44 Gurewich V. Pro-urokinase: Physiochemical properties and promotion of its fibrinolytic activity by urokinase and by tissue plasminogen activator with which it has a complementary mechanism of action. Semin Thromb Hemostas 1988; 14: 110-115
    Article in Thieme ConnectPubMedGoogle Scholar